Liposarcoma medical therapy: Difference between revisions

	Liposarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Liposarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Liposarcoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Liposarcoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Liposarcoma medical therapy
CDC on Liposarcoma medical therapy
Liposarcoma medical therapy in the news
Blogs on Liposarcoma medical therapy
Directions to Hospitals Treating Liposarcoma
Risk calculators and risk factors for Liposarcoma medical therapy

Revision as of 19:17, 19 September 2014


Drugs	Dose

Doxurubicin	Doxurubicin 75 mg/m2; 28 day cycle
Pegylated liposomal doxurubicin	40-50 mg/m2 ; 28 day cycle
AI regimen	Doxurubicin 25 mg/m2, Ifosfamide 3g/m2 21 day cycle
MAID regimen	Doxurubicin 20 mg/m2, ifosfamide 2.5g/m2, Dacarbazine 300mg/m2 21 day cycle
AD regimen	Doxurubicin 20 mg/m2, Dacarbazine 300mg/m2; 21 day cycle
Metronomic cyclophosphamide	Oral daily cyclophosphamide 50mg/day for 21 dyas on 28 day cycle
Docetaxel-Gemcitabine	Gemcitabine 900 mg/m2 , Docetaxel 100 mg/m2 for 21 day cycle
Trabectidin	Trabectidin 1.5mg/m2 21 day cycle

@@ Line 13: / Line 13: @@
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Pegylated liposomal doxurubicin
 | style="padding: 5px 5px; background: #F5F5F5;" |40-50 mg/m2 ; 28 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |AI regimen
+| style="padding: 5px 5px; background: #F5F5F5;" |Doxurubicin 25 mg/m2, Ifosfamide 3g/m2 21 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |MAID regimen
+| style="padding: 5px 5px; background: #F5F5F5;" |Doxurubicin 20 mg/m2, ifosfamide 2.5g/m2, Dacarbazine 300mg/m2 21 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |AD regimen
+| style="padding: 5px 5px; background: #F5F5F5;" |Doxurubicin 20 mg/m2, Dacarbazine 300mg/m2; 21 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Metronomic cyclophosphamide
+| style="padding: 5px 5px; background: #F5F5F5;" |Oral daily cyclophosphamide 50mg/day for 21 dyas on 28 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Docetaxel-Gemcitabine
+| style="padding: 5px 5px; background: #F5F5F5;" |Gemcitabine 900 mg/m2 , Docetaxel 100 mg/m2 for 21 day cycle
+|-
+| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Trabectidin
+| style="padding: 5px 5px; background: #F5F5F5;" |Trabectidin 1.5mg/m2 21 day cycle
 |}